ArticleQuantitative imaging in medicine and surgery2026
T1rho MRI as a quantitative biomarker of radiation-induced liver disease in normal and fibrotic rat models.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) is used for inoperable hepatocellular carcinoma (HCC) patients, yet radiation-induced liver disease (RILD) poses risks, particularly in fibrotic livers. T1rho imaging, which allows high scan-rescan stability and high sensitivity to changes from baseline measure, has emerged as a promising noninvasive biomarker for liver injury but its utility in RILD remains underexplored. This study characterizes liver T1rho change in rat models of RILD with/without pre-existing fibrosis. Methods: Male Sprague-Dawley (SD) rats were divided into radiation therapy (RT) (n=41; 25 Gy right liver irradiation) and thioacetamide (TAA) + RT (n=46; 6-week TAA-induced fibrosis + 20 Gy RT) groups. Nine control rats, and each experimental rat at the endpoint had Results: The control rats had normal liver T1rho value of 37.2±0.93 ms. An RT of 25 Gy led to an elevated liver T1rho of 40.14±1.06 ms 2 weeks post-RT (P<0.001). With TAA pre-treatment, 20 Gy RT led to an elevated liver T1rho of 45.24±1.24 ms 2 weeks post-RT, which is statistically significantly higher than the liver T1rho 2 weeks post-RT with the dosage of 25 Gy (P<0.001), suggesting pre-existing liver injury by TAA sensitizing liver to RT injury. For both the RT and TAA + RT model, there was a treatment-duration dependent elongation of liver T1rho value. Liver T1rho values were strongly correlated with collagen-based histological markers (mostly, Pearson r>0.9). Tentatively Inflammation contributed to T1rho elongation beyond collagen deposition, while ballooning degeneration did not show a notable effect on liver T1rho. Conclusions: This study demonstrates that T1rho MRI is a sensitive and noninvasive biomarker of RILD severity in rat models, reflecting both fibrosis and inflammation. These findings support its potential utility for early detection, individualized risk assessment, and mechanistic studies of RILD, particularly in clinical settings where histological validation is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.